These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 37239020)

  • 21. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
    Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.
    Liang Y; Cui L; Gao J; Zhu M; Zhang Y; Zhang HL
    Mol Neurobiol; 2021 Aug; 58(8):3745-3758. PubMed ID: 33825149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases.
    Pan I; Issac PK; Rahman MM; Guru A; Arockiaraj J
    Mol Neurobiol; 2024 Dec; 61(12):9873-9891. PubMed ID: 37851313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease.
    Chiang HL; Lin CH
    J Mov Disord; 2019 May; 12(2):67-83. PubMed ID: 31158941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prodromal non-motor symptoms of Parkinson's disease.
    Pellicano C; Benincasa D; Pisani V; Buttarelli FR; Giovannelli M; Pontieri FE
    Neuropsychiatr Dis Treat; 2007 Feb; 3(1):145-52. PubMed ID: 19300544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymannuronic acid prevents dopaminergic neuronal loss via brain-gut-microbiota axis in Parkinson's disease model.
    Dong XL; Wang X; Liu F; Liu X; Du ZR; Li RW; Xue CH; Wong KH; Wong WT; Zhao Q; Tang QJ
    Int J Biol Macromol; 2020 Dec; 164():994-1005. PubMed ID: 32710966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advances in Parkinson's disease induced by α-synuclein transmitted through the gut-brain axis].
    Zhou J; Wang Z
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2120-2127. PubMed ID: 35786466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut-oriented disease modifying therapy for Parkinson's disease.
    Lin CH; Lai HC; Wu MS
    J Formos Med Assoc; 2023 Jan; 122(1):9-18. PubMed ID: 36182642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's Disease and the Gut: Symptoms, Nutrition, and Microbiota.
    Yemula N; Dietrich C; Dostal V; Hornberger M
    J Parkinsons Dis; 2021; 11(4):1491-1505. PubMed ID: 34250955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
    Song B; Feldmann JW; Cao S; Feitosa M; Kong Y; Kim W; Schweitzer A; Leblanc P; Schweitzer JS; Kim KS
    Neurobiol Dis; 2022 Aug; 170():105777. PubMed ID: 35636646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's Disease: From Genetics and Epigenetics to Treatment, a miRNA-Based Strategy.
    Paccosi E; Proietti-De-Santis L
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial dysfunction in Parkinson's disease.
    Hu Q; Wang G
    Transl Neurodegener; 2016; 5():14. PubMed ID: 27453777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The protective role of microbiota in the prevention of MPTP/P-induced Parkinson's disease by resveratrol.
    Tao J; An Y; Xu L; Wang Y; Wang C; Li P; Li M; Yan D; Wang M; Zhong G; Wu M
    Food Funct; 2023 May; 14(10):4647-4661. PubMed ID: 37102320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Connection Between the Gut Microbiome and Parkinson's Disease Symptom Progression and Pathology: Implications for Supplementary Treatment Options.
    Chan DG; Ventura K; Villeneuve A; Du Bois P; Holahan MR
    J Parkinsons Dis; 2022; 12(8):2339-2352. PubMed ID: 36278360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
    Nielsen SD; Pearson NM; Seidler K
    Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifactorial sleep disturbance in Parkinson's disease.
    Albers JA; Chand P; Anch AM
    Sleep Med; 2017 Jul; 35():41-48. PubMed ID: 28619181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human gut microbiota and Parkinson's disease.
    Pant A; Bisht KS; Aggarwal S; Maiti TK
    Prog Mol Biol Transl Sci; 2022; 192(1):281-307. PubMed ID: 36280322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.